Apeloa Pharmaceutical Co Ltd (000739) — Capital Reinvestment Ratio
Apeloa Pharmaceutical Co Ltd (000739) has a Capital Reinvestment Ratio of 0.37x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥446.18 Million) in capital expenditures (CN¥166.73 Million). Check 000739 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Apeloa Pharmaceutical Co Ltd Capital Reinvestment Ratio (1998–2025)
This chart tracks Apeloa Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 26 annual periods. For the full cash flow conversion analysis, see Apeloa Pharmaceutical Co Ltd cash flow conversion.
Annual Capital Reinvestment Ratio for Apeloa Pharmaceutical Co Ltd (1998–2025)
Year-by-year Capital Reinvestment Ratio for Apeloa Pharmaceutical Co Ltd from 1998 to 2025. See Apeloa Pharmaceutical Co Ltd (000739) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.31x | CN¥1.23 Billion | CN¥386.21 Million | ▼ -17.7% |
| 2024 | 0.38x | CN¥1.21 Billion | CN¥460.75 Million | ▼ -37.6% |
| 2023 | 0.61x | CN¥1.03 Billion | CN¥630.47 Million | ▲ +59.2% |
| 2022 | 0.38x | CN¥1.33 Billion | CN¥509.11 Million | ▼ -66.5% |
| 2021 | 1.15x | CN¥611.75 Million | CN¥701.92 Million | ▲ +283.4% |
| 2020 | 0.30x | CN¥1.06 Billion | CN¥317.12 Million | ▲ +1178.2% |
| 2019 | 0.02x | CN¥1.36 Billion | CN¥31.85 Million | ▼ -76.1% |
| 2018 | 0.10x | CN¥832.69 Million | CN¥81.62 Million | ▼ -87.4% |
| 2017 | 0.78x | CN¥209.80 Million | CN¥163.42 Million | ▼ -57.6% |
| 2016 | 1.84x | CN¥180.42 Million | CN¥331.35 Million | ▲ +79.2% |
| 2015 | 1.02x | CN¥441.16 Million | CN¥452.06 Million | ▲ +49.2% |
| 2014 | 0.69x | CN¥786.64 Million | CN¥540.22 Million | ▼ -74.1% |
| 2013 | 2.65x | CN¥190.45 Million | CN¥505.01 Million | ▲ +162.3% |
| 2012 | 1.01x | CN¥335.90 Million | CN¥339.59 Million | ▲ +41.4% |
| 2011 | 0.71x | CN¥404.62 Million | CN¥289.21 Million | ▼ -38.1% |
| 2010 | 1.15x | CN¥121.05 Million | CN¥139.81 Million | ▲ +156.9% |
| 2009 | 0.45x | CN¥208.30 Million | CN¥93.66 Million | ▼ -87.8% |
| 2008 | 3.69x | CN¥94.57 Million | CN¥349.04 Million | ▲ +455.7% |
| 2007 | 0.66x | CN¥174.20 Million | CN¥115.70 Million | ▲ +96.7% |
| 2006 | 0.34x | CN¥159.43 Million | CN¥53.84 Million | ▼ -75.7% |
| 2005 | 1.39x | CN¥87.40 Million | CN¥121.65 Million | ▼ -40.4% |
| 2004 | 2.34x | CN¥47.54 Million | CN¥111.07 Million | ▲ +179.4% |
| 2003 | 0.84x | CN¥105.36 Million | CN¥88.09 Million | ▼ -95.0% |
| 2002 | 16.78x | CN¥2.81 Million | CN¥47.23 Million | ▲ +3595.5% |
| 2000 | 0.45x | CN¥7.08 Million | CN¥3.22 Million | ▼ -16.8% |
| 1998 | 0.55x | CN¥30.10 Million | CN¥16.43 Million | — |